A Randomized, Open-label, Multicentre Clinical Study of TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer
Overview
- Phase
- Phase 2
- Intervention
- TAS-102+bevacizumab
- Conditions
- Colorectal Cancer
- Sponsor
- Henan Cancer Hospital
- Enrollment
- 224
- Locations
- 1
- Primary Endpoint
- Time to treatment failure (TTF)
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
This study is a randomized, controlled, open-label, multicentre clinical study. This study is designed to evaluate the efficacy and safety of TAS-102 combined with bevacizumab as second-line maintenance therapy versus standard chemotherapy combined with bevacizumab as second-line continuous therapy in advanced colorectal cancer after second-line induction therapy.
Detailed Description
This study is a randomized, controlled, open-label, multicentre clinical study. This study is designed to evaluate the efficacy and safety of TAS-102 combined with bevacizumab as second-line maintenance therapy versus standard chemotherapy combined with bevacizumab as second-line continuous therapy in advanced colorectal cancer after second-line induction therapy. The primary endpoint is investigator-assessed time to treatment failure (TTF). Secondary endpoints include ORR, DCR, DoR, PFS, OS, safety and patient reported outcomes. This study plans to enroll 224 patients with advanced colorectal cancer who have previously achieved disease control after second-line induction therapy with standard chemotherapy (FOLFOX, FOLFIRI, or CAPEOX) combined with bevacizumab. The subjects will be randomly assigned in a 1:1 ratio to the TAS-102 combined with bevacizumab second-line maintenance treatment group (experimental group) and the standard chemotherapy combined with bevacizumab second-line continuous treatment group (control group).
Investigators
Ying Liu
Director
Henan Cancer Hospital
Eligibility Criteria
Inclusion Criteria
- •Subjects voluntarily participate in this study, sign the informed consent form, and have good compliance;
- •Age ≥18 years old;
- •Unresectable colorectal adenocarcinoma confirmed by histopathology or cytology;
- •After receiving 12 weeks of standard chemotherapy (FOLFOX, FOLFIRI, or CAPEOX) combined with bevacizumab second-line induction therapy, the patients are confirmed as CR, PR, or SD according to RECIST 1.1 criteria;
- •The interval between the last second-line induction therapy and randomization is not more than 6 weeks;
- •At least one measurable lesion according to RECIST 1.1 criteria;
- •ECOG Performance Status 0-2;
- •Estimated life expectancy ≥12 weeks;
- •Adequate major organ function (no medication for blood component, cell growth factor correction therapy is allowed within 14 days before randomization);
- •Women of child-bearing potential must agree to abstain from sex (heterosexual intercourse) or use a reliable, effective method of contraception from the time they provide informed consent until at least 90 days after the last dose of study drug is administered. Serum or urine HCG test must be negative. And must be non-lactating;
Exclusion Criteria
- •Any CTCAE grade 1 or above toxicity caused by previous treatment that has not yet subsided (excluding alopecia, skin pigmentation, and chemotherapy-induced neurotoxicity);
- •Known history or evidence of interstitial lung disease or active noninfectious pneumonia;
- •Poorly controlled hypertension (systolic blood pressure \>150 mmHg and/or diastolic blood pressure \>100 mmHg) with a previous history of hypertensive crisis or hypertensive encephalopathy;
- •Have bleeding tendency and high risk of bleeding;
- •Known inherited or acquired bleeding (e.g., coagulopathy) or thrombophilia, as in patients with hemophilia; Current or recent (within 10 days before initiation of study treatment) use of a full-dose oral or injectable anticoagulant or thrombolytic agent for therapeutic purposes (prophylactic use of low-dose aspirin and low-molecular-weight heparin is allowed);
- •Thrombotic or embolic events, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), pulmonary embolism, etc., occurred within 6 months before the initiation of study treatment;
- •Severe, unhealed or dehiscence wounds and active ulcers or untreated fractures;
- •Has undergone major surgical treatment (excluding diagnosis) within 4 weeks before the start of the study or is expected to undergo major surgical treatment during the study period;
- •Inability to swallow tablets, malabsorption syndrome or any condition affecting gastrointestinal absorption;
- •Patients with congenital or acquired immune deficiency (such as HIV infection);
Arms & Interventions
second-line maintenance treatment group
TAS-102 combined with bevacizumab
Intervention: TAS-102+bevacizumab
second-line continuous treatment group
Standard chemotherapy (FOLFOX，FOLFIRI or CAPEOX) combined with bevacizumab
Intervention: Standard chemotherapy+bevacizumab
Outcomes
Primary Outcomes
Time to treatment failure (TTF)
Time Frame: up to approximately 2 years.
TTF is defined as the time from the date of randomization to the date of the discontinuation of the trial protocol.
Secondary Outcomes
- Adverse Events(up to approximately 2 years.)
- Disease control rate (DCR)(up to approximately 2 years.)
- Duration of Response (DoR)(up to approximately 2 years.)
- Progression-free survival (PFS)(up to approximately 2 years.)
- Overall survival（OS）(up to approximately 2 years.)
- Objective response rate (ORR)(up to approximately 2 years.)
- European Quality of Life Five Dimensions Five Level Scale Questionnaire (EQ-5D-5L)(up to approximately 2 years.)
- European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30)(up to approximately 2 years.)